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Edited by Gianni CesareniAbstract Cross-talk between ERa and STAT5a was demon-
strated to mediate through a direct physical association between
the two proteins. By GST pull-down assays and functional assays
with various constructs of ERa and STAT5a, it was shown that
the C-termini of these two proteins were mainly responsible for
this interaction. Furthermore, the interaction between ERa and
STAT5a was demonstrated to give rise to functional changes in
their signaling events. In cell transfection studies, it was shown
that ERa activation could attenuate PRLR signaling through
STAT5a. This ERa-mediated attenuation of PRLR signaling
was substantiated by observed decreases in the phosphorylation
of JAK2 and STAT5a, reduced translocation of STAT5a into
the nucleus, and reduced binding of STAT5a onto a GAS-
containing nucleotide. Apart from transfected cells, the interac-
tion between ERa and STAT5a could also be observed in
established breast cancer cell lines of MCF-7 and T-47D in co-
immunoprecipitation studies. However, the functional conse-
quence of the interaction in these cancer cells was very diﬀerent
from the transfected HEK293 cells. ER activation could lead to
potentiation of PRLR signaling in MCF-7 cells but not in T-47D
cells. Conversely, in both MCF-7 and T-47D cells, PRLR
activation could lead to attenuation of ER signaling. These data
serve to elucidate the mechanisms underlying the ERa–STAT5a
cross-talk and in demonstrating that the functional consequence
of this cross-talk depends on the precise milieus of the
intracellular environment.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Both the steroid hormone estrogen and the polypeptide
hormone prolactin (PRL) are important regulatory factors in
mammary gland development and diﬀerentiation [1,2]. They
could induce distinct signaling transduction pathways on tar-
get cells. Estrogen exerts most of its biological eﬀects through
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doi:10.1016/j.febslet.2004.06.098(ER) [3]. The estrogen activated ERs form dimers and subse-
quently associate with speciﬁc consensus DNA sequences
called estrogen response elements (ERE) located in the pro-
moter regions of target genes to regulate gene transcription.
ER is a member of the nuclear receptor superfamily and shares
the common protein structure of this family [4,5]. The protein
can be divided into several functional domains, denoted as A
to F from the N terminus to the C terminus. The most con-
served DNA-binding domain (DBD) C is comprised of two
distinct zinc ﬁngers and is responsible for DNA-binding and
protein dimerization. The C-terminal E domain or ligand-
binding domain (LBD) plays important roles in mediating li-
gand binding, receptor dimerization, nuclear translocation,
and ligand-dependent transactivation (AF-2) of target gene
expression. The N-terminal A/B domain is highly variable in
both sequence and size. It usually contains a transactivation
function (AF-1), which activates target genes by directly in-
teracting with components of the core transcription machinery
or with coactivators that mediate signaling to the downstream
proteins. The hinge domain D contributes ﬂexibility to the
DBD versus LBD and has also, in some cases, been shown to
inﬂuence the DNA-binding properties of individual receptors,
thus serving as an anchor for certain co-repressor proteins.
Finally, the C-terminal F domain has been shown to contrib-
ute to the transactivation capacity of the receptor. But its other
functions, if any, are to a large extent unknown.
PRL induced its biological eﬀects through the membrane
bound PRL receptor (PRLR) and the Janus kinase (JAK) and
signal transducers and activators of transcription (STAT)
signaling cascade, mainly activating JAK2 and STAT5, in-
cluding STAT5a and STA5b proteins [6,7]. Once bound to its
ligand, PRLR dimerizes and activates JAK2. The activated
JAK2, in turn, mediates phosphorylation of speciﬁc receptor
tyrosine residues of PRLR, which then serve as docking sites
for STAT5 proteins and other signaling molecules. Once re-
cruited to the receptor, STAT5 also become phosphorylated by
JAK2 on a single tyrosine residue located at the C-terminus.
This is followed by the dissociation of STAT5 from PRLR and
the formation of STAT5 dimers, which migrate into the nu-
cleus to bind to c-activated sequence element (GAS site) in the
promoters of cytokine-responsive genes.
Functional interaction between steroid hormone receptors
and STAT5 has been proposed [8–14]. For example, cross-talk
between glucocorticoid receptor (GR) and STAT5a has been
reported. GR and STAT5a have been shown to interact in
both transiently transfected cells [8] and in mammary epithelialblished by Elsevier B.V. All rights reserved.
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regulated b-casein promoter in transiently transfected COS
cells. Recruitment of GR to the promoter by STAT5a leads to
a supplementation of the STAT5a transactivation ability by
the stronger GR transactivation domain [9]. Enhancement of
STAT5a activity by GR might be the result of a protein in-
teraction between GR and STAT5a, which enhance and pro-
long the DNA binding ability of STAT5a [11,13]. Synergy
between STAT5 and progesterone receptor (PR) or mineral-
corticoid receptor (MR) has also been reported [10]. In these
instances, the steroid hormone receptors were reported to exert
a negative inﬂuence on STAT5a transactivation through a
physical interaction with STAT5a [10,14].
In the present work, functional interaction between ERa
and STAT5a signaling was identiﬁed and co-immunoprecipi-
tation was performed to conﬁrm the binding between ERa and
STAT5a. The domain(s) involved in this functional interaction
in each protein was mapped using either functional assays or
glutathione S-transferase (GST) pull-down assays. STAT5a
activation events, including tyrosine phosphorylation, DNA
binding and nuclear translocation were investigated in the
presence or absence of ERa co-expression. In addition to the
co-transfection system, two human breast cancer cell lines,
MCF-7 and T-47D, which naturally express ERa and STA-
T5a, were used to investigate the functional interaction be-
tween ERa and STAT5a. Our data contribute to a better
understanding of the mechanisms underlying ERa-STAT5a
cross-talk.2. Materials and methods
2.1. Plasmids
ThepSG5-MORmouseERa-containing plasmidwas kindly provided
by Dr. Parker of Imperial College London, UK. The pXM-STAT5a
plasmid was kindly provided by Dr. Hennighausen of the National In-
stitutes of Health, USA. The pcDNA3-hPRLR plasmid containing the
long form human PRLRwas constructed as described [15]. For theGST
fusion constructs, the DBD of STAT5a was ampliﬁed by the forward
primer: 50-ACC AGC ACG TTC ATC ATC GAG-30 and the reverse
primer: 50-GCC CCG GTT GCT CTG TAC TT-30. The Src-homology
2(SH2)-transcription activation domain (TAD) fragment of STAT5aFig. 1. ERa binds to the C-terminus of STAT5a. Panel A is a schematic repres
down assays, one containing the DBD alone and the other containing the
phorylation position. Panel B shows the results of the various immobilized
transfected and E2 treated HEK293 cells. Speciﬁcally bound ERa was visuawas ampliﬁed by the forward primer: 50-TTC TGG CAG TGG TTC
GACGG-30 and the reverse primer: 50-ACCAGCACGTTCATCATC
GAG-30. BothDNA fragments were inserted in frame into theSma I site
of theGST expressing vector pGEX-4T-1 by blunt-end ligation. Various
ERamutants were generated by PCR (18 cycles of 92 C for 45 s, 62 C
for 45 s and 72 C for 2 min) using a set of mouse ERa gene speciﬁc
primers (ER-F1: 50-GGGA TCCATGCACACCAAAGCCTCG-30;
ER-F2: 50-G GGA TCC ATG TAC TGT GCCGTG TGC-30; ER-F3:
50-G GGA TCC ATG GTC AGT GCC TTG TT-30; ER-R1: 50-G
GAA TTCTCAGATCGTGTTGGGG-30; ER-R2: 50-GGAA TTC
TCA ATG AAG GCG GTG GGC A-30; and ER-R3: 50-G GAA TTC
TCACAT CTGGTCAGCTGTC-30). BamH I and EcoR I restriction
sites were introduced in the forward and reverse primers, respectively, to
facilitate subsequent subcloning. The DNA fragments were inserted in
frame into the eukaryotic expressionvector pBK/CMV.The inserts of all
the plasmids used in this study were checked by DNA sequencing to
avoid mutations.
2.2. Cell culture, transfection and luciferase assays
Human embryonic kidney (HEK) 293 cells were cultured in DMEM
containing 5% fetal bovine serum (FBS), 1 antibiotics P/S (100 U/ml
penicillin and 100 lg/ml streptomycin). Transfection was performed
using the Lipofectamine Reagent (Invitrogen) according to the
manufacturer’s protocol. Brieﬂy, 2 105/well cells were seeded in poly-
D-lysine pre-coated 24-well plate in phenol red-free MEM (Sigma)
containing 1% charcoal-stripped FBS for 24 h before transfection.
Luciferase (LUC) was used as the reporter gene. The reporter plasmids
(ERE-LUC or b-casein-LUC, 500 ng), together with the PRLR,
STAT5a or ERa expression plasmids, were co-transfected into the
cultured cells as indicated in the ﬁgure legends. The water-soluble 17b-
estradiol (E2) (Sigma) (ﬁnal concentration 10
8 M), ovine PRL
(oPRL) (Sigma) (ﬁnal concentration 1 lg/ml), a combination of both,
or just the vehicle alone were added to the cells as indicated in the
ﬁgure legends. Hormone treatment lasted for 24 h before the cells were
lysed for the LUC assays.
The human breast cancer cell lines MCF-7 and T-47D were routinely
kept in MEM containing 5% FBS and 1 P/S. Before use, the medium
was changed to phenol red-free MEM containing 1% charcoal-stripped
FBS for 48 h. Five hundred nanograms of either ERE-LUC or b-ca-
sein-LUC reporter was transfected using the same protocol. Hormone
treatment was performed as indicated in the ﬁgure legends for 24 h
before LUC assays.
LUC assays were performed using the Dual-Luciferase Reporter
System (Promega) with the proper control normalization vector (Re-
nilla luciferase).
2.3. GST pull-down assays
GST pull-down assays were performed using the Profound Pull-
Down GST Protein: Protein Interaction Kit (Pierce). Expression ofentation of the two GST-fusion STAT5a mutants used in the GST pull-
SH2-TAD domains. The black triangle indicates the tyrosine phos-
GST-fusion proteins co-incubated with lysates prepared from ERa
lized by Western blotting using an anti-ERa antibody.
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The induced culture (5 ml) was collected and lyzed. The bacterial ex-
pressed GST-fusion proteins were then immobilized on a glutathione
gel to serve as bait proteins in the subsequent steps. Total proteins (500
lg) from HEK293 cells transfected with ERa were incubated with each
immobilized GST-tagged bait protein and the bait-prey elution was
then analyzed by Western blot by probing the ERa.
2.4. Whole cell extract (WCE) preparation
HEK293 cells (1 107/dish) in 100 mm tissue culture dish were
transiently transfected with 5 lg ERa and 5 lg STAT5a expression
plasmids together with 500 ng of the PRLR expression plasmid for
inducing the PRL signal. Transfections using either ERa alone, or
STAT5a plus PRLR were used as controls. After incubation in the
transfection medium for 5 h, cells were recovered in phenol red-free
MEM containing 1% charcoal-stripped FBS for 24 h. The cells were
then stimulated for 30 min with 1 lg/ml oPRL, 108 M E2, a combi-Fig. 2. ERa inhibits PRL-induced STAT5a-mediated transcription activation
plasmid together with expression vectors containing PRLR (50 ng), STAT5a
separate experiment, HEK293 cells were co-transfected with 500 ng ERE-L
creasing amount of STAT5a (50–200 ng) (Panel B). The total amount of DN
vector pcDNA3. The transcription responses to 108 M E2, 1 lg/ml oPRL,
control) were determined. The Renilla luciferase internal control plasmid was
Panel C, HEK293 cells were co-transfected with 500 ng b-casein-LUC report
STAT5a (100 ng) and various ERa mutants (50 ng). The left hand side of Pan
ml oPRL (open bars) or a combination of 1lg/ml oPRL and 108 M E2 (str
assays were performed in duplicates. Data are presented as means S.D.
Tukey’s multiple comparison test. Panel A: *, P < 0:05 compared against
comparing (E2+oPRL) against (oPRL); @, P < 0:01 comparing (E2+oPRL) a
statistical signiﬁcance was observed between (E2+oPRL) and (oPRL) in all c
compared against oPRL only.nation of both, or just the vehicle alone. Cells were brieﬂy washed with
ice-cold 1 PBS, collected in an Eppendorf tube, and lysed in lysis
buﬀer (20 mM HEPES, pH 7.5, 0.4 M KCl, 0.1 mM EDTA and 0.1%
NP-40) supplemented with a protease inhibitor cocktail (Roche) con-
taining 2 lg/ml aprotinin, 2 lg/ml benzamidine, 2 lg/ml soybean
trypsin inhibitor, 1.5 lg/ml leupeptin, 1 mM sodium orthovanadate
and 1 mM sodium molybdate. Lysates were centrifuged at 12 000 g
for 15 min at 4 C to remove the debris and protein concentrations
were measured by the BCA method (Bio-Rad). All extracts were ali-
quoted, frozen in liquid nitrogen, and stored at )80 C until use. Each
aliquot was thawed only once.
2.5. Co-immunoprecipitation studies
WCE (400 lg) from each sample was used in the co-immunopre-
cipitation studies. Immunoprecipitation was carried out at room
temperature for 2 h by adding 40 lg of anti-ERa antibody (H-184)
(Santa Cruz Biotechnology, Inc.) and protein G-agarose beads (Sig-. HEK293 cells were co-transfected with 500 ng b-casein-LUC reporter
(100 ng) and increasing amounts of ERa (50–200 ng) (Panel A). In a
UC reporter plasmid together with 100 ng ERa, 50 ng PRLR and in-
A used in each transfection was adjusted to 1 lg/well with the empty
or a combination of both, or just the vehicle alone (NH¼ no hormone
also co-transfected to correct for diﬀerences in transfection eﬃciency. In
er plasmid together with expression vectors containing PRLR (50 ng),
el C shows the ERa mutants used. The transcription responses to 1 lg/
ipped bars) are shown on the right hand side of Panel C. All luciferase
(n ¼ 6). Statistical analysis was performed by ANOVA, followed by
NH control; **, P < 0:01 compared against NH control; x, P < 0:05
gainst (oPRL). Panel B: **, P < 0:01 compared against NH control; no
ases. Panel C: *, P < 0:05 compared against oPRL only; **, P < 0:01
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by Western blotting with an antibody probing STAT5a (L-20) (Santa
Cruz Biotechnology, Inc.). For detecting tyrosine phosphorylated
STAT5a and JAK2, STAT5a and JAK2 were ﬁrst captured by im-
munoprecipitation with an anti-STAT5a antibody or an anti-JAK2
antibody (C-20) (Santa Cruz Biotechnology, Inc.). The precipitated
proteins were analyzed with a phosphotyrosine speciﬁc antibody
(PY20) (Santa Cruz Biotechnology, Inc.).
2.6. Electrophoretic mobility shift assays (EMSA)
An oligonucleotide encompassing the b-casein GAS site was used for
EMSA. The sequence of the coding strand was as follows: 50-TA-
ATCATGTGGACTTCTTGGAATTAAGGGACTTTT-30. Sense and
antisense oligonucleotides were synthesized and labeled with biotin
using the Biotin 30-End DNA Labeling Kit (Pierce). Double stranded
DNA was formed by annealing the single chain oligonucleotides at
room temperature for at least 30 min after heating together at 80 C
for 15 min in 1 annealing buﬀer (20 mM Tris–Cl, pH 7.5, 10 mM
MgCl2 and 50 mM NaCl). EMSA was performed using the LightShift
Chemiluminescent EMSA Kit (Pierce). Brieﬂy, the total protein and
the labeled probe were incubated together with 2 ll of poly (dI)-poly
(dC) (1 lg/ll) and 2 ll 10 binding buﬀer (100 mM Tris, 500 mM KCl
and 10 mMDTT, pH 7.2) in a total volume of 20 ll per reaction for 20
min at room temperature. The reaction mixtures were resolved on a 4%
native polyacrylamide gel containing 0.5 TBE. Biotin-labeled DNA
was detected according to the manufacturer’s protocol.
2.7. Subcellular fractionation
Nuclear extracts were prepared using the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce). Cells were collected by
scraping and then washed brieﬂy with 1 PBS. After careful removal of
the supernatant, the cell pellet was lyzed and layered by centrifugation
at 16 000 g for 5 min at 4 C. The supernatant containing the cyto-
plasmic components was carefully removed. The nuclear pellet was
further lyzed and cleaned by another round of centrifugation at
16 000 g for 10 min at 4 C. The nuclear extracts were stored at )80 C
in aliquots after protein determination.Fig. 3. Co-immunoprecipitation of STAT5a with ERa. HEK293 cells
were transfected with expression vectors containing PRLR, STAT5a
and ERa (Lanes 3–6), or with just PRLR and STAT5a (Lane 1), or
with ERa alone (Lane 2). Cells were treated for 30 min with 1 lg/ml
oPRL, or 108 M E2, or a combination of both, or just the vehicle
alone (NH¼ no hormone control) before lyzed for co-immunopre-
cipitation studies. Four hundred micrograms of total protein in each
lysate were incubated with 40 lg anti-ERa antibody. The amount of
co-immunoprecipitated STAT5a was analyzed by Western blotting
with an anti-STAT5a antibody (Panel A). The expression levels of
STAT5a (Panel B) and ERa (Panel C) in the cells were examined using
20lg of total protein from each cell lysate in the SDS–PAGE followed
by Western blotting with an anti-STAT5a antibody or an anti-ERa
antibody.3. Results
The C-terminal SH2-TAD domains of STAT5a and the
N-terminal DBD were expressed as GST fusion proteins and
tested for their binding abilities with ERa expressed in
HEK293 cells activated with E2. As shown in Fig. 1, only
the STAT5a fragment containing the C-terminal SH2-TAD
domains showed an ERa speciﬁc band after Western blot
analysis, whereas the fragment containing the DBD did not
bind with ERa. This thus raises the possibility that ERa
may bind to STAT5a through the C-terminus of STAT5a.
This physical interaction is functionally signiﬁcant, as
demonstrated in Fig. 2. STAT5a activation through ligand
stimulation of PRLR, as demonstrated by the b-casein-LUC
reporter gene, was attenuated by ERa activation (Fig. 2A). On
the other hand, however, ERa activation, as demonstrated by
the ERE-LUC reporter gene, was not aﬀected by STAT5a
activation (Fig. 2B). Furthermore, using diﬀerent ERa deletion
mutants in the functional assays, it was found that deletion of
the ERa C-terminal domains, including the F, E, and C do-
mains, caused obvious attenuation of the inhibitory eﬀects,
while deletion of the A/B domain had no eﬀect, indicating that
the inhibition of the PRL-induced b-casein-LUC expression by
E2 could be attributed to the C-terminal C-F domains of ERa,
but not the N-terminal A/B domain (Fig. 2C). Within the same
assay, we found that among all the mutants, the plasmid
containing C-F portion of ERa exhibited the highest inhibi-
tory potency among all the ERa mutants. The mutant con-
taining the C-E domains also exerted considerable inhibitoryactivities on STAT5a transactivation but was less eﬀective than
the C-F domains. The C domain alone or the E/F domain
alone failed to inhibit reporter expression. These results indi-
cated that the entire C-terminal C-F domains contributed to
maximum inhibition of STAT5a transactivation, while the
core region for such an inhibition was the C-E domains. In-
clusion of the F domain increases the inhibitory activity of the
core region.
Co-immunoprecipitation experiments were performed to
conﬁrm the protein–protein interaction between ERa and
STAT5a expressed in HEK293 cells (Fig. 3). In these experi-
ments, HEK293 cells were transfected with both ERa and
STAT5a together with PRLR to induce the PRL signal (Fig. 3,
Lanes 3–6). Transfections with either ERa alone (Fig. 3, Lane
2) or PRLR plus STAT5a (Fig. 3, Lane 1) were used as con-
trols. Precipitation of STAT5a by ERa speciﬁc antibody was
observed in conditions when ERa and STAT5a were co-ex-
pressed, regardless of the presence or absence of E2 and/or
oPRL (Fig. 3A, Lanes 3–6), indicating that the ERa–STAT5a
interaction is a hormone independent event. In the absence of
ERa, the STAT5a protein could not be co-immunoprecipi-
tated (as indicated in Lane 1 of Fig. 3A). A weak STAT5a
band also appeared under the condition when ERa alone was
transfected (as indicated in Lane 2 of Fig. 3A). This was
probably due to the endogenous expression of STAT5a protein
in HEK293 cells (as indicated in Lane 2 of Fig. 3B). Western
blot analyses probing STAT5a (Fig. 3B) or ERa (Fig. 3C)
revealed that the observed results could not be attributed to
changes in the expression levels of STAT5a and ERa.
In the JAK-STAT pathway, STAT is activated through
phosphorylation by cytokine receptor-associated JAK tyrosine
kinase, which is also activated by phosphorylation. Activated
STAT protein then dimerizes and translocates into the nucleus
to regulate target gene transcription. These STAT activation
events have also been examined upon ERa–STAT5a interac-
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HEK293 cells were transfected with STAT5a and PRLR, or
with STAT5a, PRLR and ERa, and then treated with oPRL
alone, or with both E2 and oPRL. By using a phosphotyrosine
speciﬁc antibody, we found that STAT5a phosphorylation was
signiﬁcantly repressed upon ERa co-expression as compared
with the no ERa control (Fig. 4A, upper panel). In the same
assay, JAK2 phosphorylation level was also found to be in-
hibited upon ERa co-expression (Fig. 4A, lower panel). And
the results were not due to the altered expression of either the
STAT5a or JAK2 protein in both situations. In EMSA, an
oligonucleotide encompassing the GAS site was used as the
probe to assess the STAT5a DNA-binding ability. When
STAT5a and ERa were co-expressed in the cultured cells, a
decrease in the intensity of the PRL-induced STAT5a-DNA
complex was observed as compared to the band intensity of the
same complex when only STAT5a was transfected. Further-
more, nuclear extracts were prepared from these transfections
and probed for STAT5a. PRL stimulation was able to trigger
nuclear translocation of STAT5a (Fig. 4C, Lanes 1 and 2). An
increase in the nucleus located STAT5a was also observed in
cells co-expressing STAT5a and ERa treated with PRL asFig. 4. ERa decreases STAT5a phosphorylation, DNA-binding and nuclear
containing plasmids with or without ERa as indicated. Cells were then treated
for no hormone control. Panel A shows the results of the STAT5a and JAK
anti-STAT5a or anti-JAK2 antibodies. Western blotting was then perform
STAT5a and JAK2 in the cells were examined using anti-STAT5a and anti-
binding. The solid arrow indicates the PRL induced complex that contains S
results of the STAT5a nuclear translocation. Nuclear fractions of transfected
SDS–PAGE followed by Western blot analyses probed with anti-STAT5a acompared to the no hormone control (Fig. 4C, Lane 3). Fur-
ther addition of E2 caused a more obvious decrease in the
nucleus located STAT5a level. Interestingly, the nucleus ERa
level remained the same in cells expressing only ERa or co-
expressing ERa and STAT5a (Fig. 4C, lower panel). This
could be due to the fact that ER, unlike other steroid hormone
receptors, is predominantly a nuclear protein regardless of
whether or not it is complexed with the ligand [3,16].
Since both E2 and PRL play crucial roles in mammary gland
development, diﬀerentiation and tumorigenesis, it would be
revealing to see whether the ER–STAT5 cross-talk actually
takes place in cells of mammary gland origin. Thus, two hu-
man breast cancer cell lines, MCF-7 and T47D, which express
ER, PRLR as well as STAT5, were employed to study such
events. Direct association of ERa and STAT5a was identiﬁed
in lysates from both cell lines by co-immunoprecipitation
studies (Fig. 5A). In functional assays, both cells were trans-
fected with the ERE-LUC reporter plasmid and treated with
E2 alone, or E2 plus oPRL at diﬀerent concentrations (10–100
ng/ml), to investigate whether addition of oPRL will inﬂuence
the ER signaling. Data from this assay indicated that addition
of PRL repressed ER signaling in both cell lines (Fig. 5B). Totranslocation. HEK293 cells were transfected with PRLR and STAT5a
for 30 min with 1 lg/ml oPRL and/or 108 M E2 as shown. NH stands
2 phosphorylation. Cell lysates (400 lg) were immunoprecipitated with
ed with an anti-phosphotyrosine antibody. The expression levels of
JAK2 antibodies. Panel B shows the EMSA results of STAT5a-DNA
TAT5a. The open arrow indicates the free probes. Panel C shows the
HEK293 cells were prepared, and 50 lg of each was separated on a 10%
nd ERa antibodies.
Fig. 5. ER and PRL signaling cross-talk in human breast cancer cells. MCF-7 and T-47D cell lysates were immunoprecipitated with an anti-ERa
antibody and probed with an anti-STAT5a antibody (Panel A). Eﬀects of PRL on E2 induced transcription activity (Panel B) and eﬀects of E2 on
PRL induced transcription activity (Panel C) were investigated in both MCF-7 and T-47D cells. The luciferase activity was expressed as a percentage
relative to the control when E2 alone (Panel B) or oPRL alone (Panel C) was used. All luciferase assays were performed in duplicates. Data are
presented as meansS.D. (n ¼ 6). Statistical analysis was performed by ANOVA, followed by Tukey’s multiple comparison test (*, P < 0:05; **,
P < 0:01).
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transfected with the b-casein-LUC reporter plasmid and trea-
ted with oPRL alone, or oPRL plus E2 at diﬀerent concen-
trations (0.01–10 nM). It was observed that addition of E2
enhanced PRL signaling in MCF-7 cells but not in T-47D cells
(Fig. 5C).4. Discussion
ER has been reported to interact with some STAT proteins
[14,17,18]. In the present study, a physical association between
ERa and STAT5a was clearly demonstrated in co-immuno-
precipitation experiments in the transfected HEK293 cells. It is
interesting to note that this protein–protein interaction was
observable even in the absence of ligand stimulation. Early
research on the cross-talk between GR and STAT5a also in-
dicated that interaction between GR and STAT5a is not hor-
mone dependent [13]. It is therefore possible that interaction
between steroid hormone receptors and STAT proteins may
exist widely in diﬀerent tissues that express these proteins.
However, enhancement of protein binding and repression ofSTAT5a activation in the presence of hormone were observed
in this study. The role of the hormonal ligands in the cross-talk
needs further investigation.
More importantly, this physical interaction between the
ERa and STAT5a was demonstrated to give rise to functional
changes in their signaling events. In transfected HEK293 cells,
it was shown that ERa activation could attenuate PRLR sig-
naling through STAT5a. Involvement of the TAD domain of
STAT5a in the protein–protein interaction provided a direct
transrepression mechanism. Functional determination of do-
mains in ERa that are required to mediate this repression of
STAT5a transactivation revealed the signiﬁcance of the C to F
domains in ERa. An early study on ER–STAT5 cross-talk [14]
reported that the interaction relies on highly speciﬁc binding
via the DBD and pointed out an indispensable role of the LBD
of ER for a suﬃcient repression of STAT5 activity. In our
experiments, the ERa mutant containing the C to E domains
was demonstrated to be the shortest fragment which was able
to inhibit STAT5a transactivation. Either the DBD alone or
the LDB alone could not repress STAT5a activity. Our func-
tional study further suggested that inclusion of the F domain
into the core inhibitory region (C to E domains) enhanced the
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reported to contribute to the transactivation capacity of ER, as
well as receptor dimerization and co-activator interaction [19].
Thus, an integral F domain may help in LBD transrepression,
or in the stability of the ERa–STAT5a complex.
This ERa-mediated attenuation of PRLR signaling was
further substantiated by observed decreases in the phosphor-
ylation of JAK2 and STAT5a, reduced translocation of
STAT5a into the nucleus, as well as reduced binding of
STAT5a onto the GAS-containing nucleotide. These might be
subsequent to the involvement of the SH2 domain of STAT5a
in the protein–protein binding. In STAT protein, SH2 domain
is responsible for recruiting STAT5a to the cytokine receptor,
STAT association to JAK kinase as well as the phosphoryla-
tion, dimerization, DNA-binding and nuclear translocation of
STAT [20–23]. Involvement of JAK2 in receptor cross-talk
recently reported that estrogen inhibits GH signaling by re-
pressing GH-induced JAK2 phosphorylation [24]. However, a
direct protein–protein interaction between ERa and JAK2 was
not found in both experiments. The underlying mechanisms
and the biological signiﬁcance remain unknown.
In the present investigation, ERa–STAT5a binding was also
identiﬁed in breast cancer cell lines but the functional outcome
of such an interaction was very diﬀerent from that in the
HEK293 cells. Because of the biological complexities of the
cells, the observed changes could result from a variety of
possible factors such as the existence of ERb, other STAT
proteins, or other signaling pathways. The autocrine/paracrine
nature of estrogen and PRL in MCF-7 and T-47D cells should
also be taken into consideration [25–27]. Finally, co-activators
or co-repressors may play important roles in the receptor
cross-talk. Both ER and STAT5 may interact with additional
factors called co-activators or co-repressors to mediate either
activation or repression of target gene expression. Some of
these cofactors are even shared in both signaling pathways.
For example, a STAT cofactor known as the suppressor of
cytokine signaling 2 (SOCS2) was suggested to be indispens-
able for inhibition of GH signaling caused by estrogen [24].
Another example is CBP/p300, which was previously suggested
to serve as an integrator of multiple signal transduction
pathways [28–30]. Limiting amount of this transcription co-
activator was thought to result in the negative cross-talk be-
tween steroid hormone receptor and AP-1 activity, although a
recent study revealed that CBP/p300 did not participate in the
STAT5-mediated suppression of GR action [14]. The eﬀects of
these other cofactors in ER–STAT5 cross-talk warrant further
investigations.
In conclusion, results of the present study revealed some
mechanisms of steroid hormone regulation of peptide hor-
mone action, and would have signiﬁcance beyond estrogen and
PRL.
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